CircBA9. 3 supports the survival of leukaemic cells by up-regulating c-ABL1 or BCR-ABL1 protein levels
Y Pan, J Lou, H Wang, N An, H Chen, Q Zhang… - Blood Cells, Molecules …, 2018 - Elsevier
The unchecked tyrosine kinase activity of BCR-ABL1 contributes to the immortality of
leukaemic cells. Therefore, this oncogene is a highly important therapeutic target for chronic
myelogenous leukaemia (CML). Tyrosine kinase inhibitors (TKIs) are an excellent drug
treatment for CML patients. However, there are still some patients who are not responsive to
TKIs. We found that a novel circular RNA (circRNA), named circBA9. 3, is derived from BCR-
ABL1. CircBA9. 3 can efficiently promote the proliferation and inhibit apoptosis of cancer …
leukaemic cells. Therefore, this oncogene is a highly important therapeutic target for chronic
myelogenous leukaemia (CML). Tyrosine kinase inhibitors (TKIs) are an excellent drug
treatment for CML patients. However, there are still some patients who are not responsive to
TKIs. We found that a novel circular RNA (circRNA), named circBA9. 3, is derived from BCR-
ABL1. CircBA9. 3 can efficiently promote the proliferation and inhibit apoptosis of cancer …
